RAP1B

Across TCGA pan-cancer cohorts, RAP1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAP1B data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RAP1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAP1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, PRAD, and UCEC are the cancer types where RAP1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.088	0.691	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.622	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RAP1B–SKCM (DFS)

Open the SKCM breakdown →